Illumina Completes Acquisition of Verinata Health

  Illumina Completes Acquisition of Verinata Health

Business Wire

SAN DIEGO -- February 21, 2013

Illumina, Inc. (NASDAQ: ILMN) today announced it has completed its previously
announced acquisition of Verinata Health, Inc., a leading provider of
non-invasive tests for the early identification of fetal chromosomal
abnormalities. As of the close, Verinata Health became a wholly owned
subsidiary of Illumina.

“We look forward to working with the talented team at Verinata to quickly
integrate our two companies,” said Jay T. Flatley, President and Chief
Executive Officer of Illumina. “Verinata was founded with a mission to improve
maternal and fetal health via the development of the verifi® prenatal test, a
non-invasive prenatal test (NIPT) for high-risk pregnancies. As an innovator
in the NIPT field, Verinata was the first provider to expand the test offering
to include sex abnormalities. Bringing our two companies together provides a
very strong collection of technologies and partners in the reproductive health
market, with solutions that will lead to improved health outcomes.”

With completion of the acquisition, Illumina now has access to Verinata’s
verifi prenatal test and to the most comprehensive intellectual property
portfolio in the NIPT industry. As previously announced, the verifi test will
continue to be offered through Verinata’s CLIA- and CAP-accredited laboratory,
and the company will continue to generate the clinical data necessary for
future regulatory submissions.

About Illumina

Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer
of life science tools and integrated systems for the analysis of genetic
variation and function. We provide innovative sequencing and array-based
solutions for genotyping, copy number variation analysis, methylation studies,
gene expression profiling, and low-multiplex analysis of DNA, RNA, and
protein. We also provide tools and services that are fueling advances in
consumer genomics and diagnostics. Our technology and products accelerate
genetic analysis research and its application, paving the way for molecular
medicine and ultimately transforming healthcare.

Forward-Looking Statements

This release may contain forward looking statements that involve risks and
uncertainties. Important factors that could cause actual results to differ
materially from those in any forward-looking statements are detailed in our
filings with the Securities and Exchange Commission, including our most recent
filings on Forms 10-K and 10-Q, or in information disclosed in public
conference calls, the date and time of which are released beforehand. We do
not intend to update any forward-looking statements after the date of this
release.

Contact:

Illumina, Inc.
Investors:
Rebecca Chambers, 858-255-5243
rchambers@illumina.com
or
Media:
Jennifer Temple, 858-882-6822
pr@illumina.com
 
Press spacebar to pause and continue. Press esc to stop.